share_log

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Calais Philippe

SEC announcement ·  Jun 19 04:20
Summary by Futu AI
Philippe Calais, associated with Transcode Therapeutics, Inc. [RNAZ], has been involved in a transaction dated 06/14/2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, have not been disclosed. The relationship of Philippe Calais to the issuer has not been specified in the announcement. As such, the impact of this transaction on Calais's holdings in Transcode Therapeutics remains unclear.
Philippe Calais, associated with Transcode Therapeutics, Inc. [RNAZ], has been involved in a transaction dated 06/14/2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, have not been disclosed. The relationship of Philippe Calais to the issuer has not been specified in the announcement. As such, the impact of this transaction on Calais's holdings in Transcode Therapeutics remains unclear.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.